Superworth

Arvinas profit margin ARVN

Gross, operating and net profit as a share of revenue over the last twelve months, from 2024.

Net margin, 12 months
2.9%
Operating margin, 12 months
−5.7%
Net margin on a year earlier
+22.4 pts
Peer median
11.6%

Over the twelve months to Jun 30, 2026, Arvinas kept 2.9% of its revenue as net profit, with an operating margin of −5.7%.

The median for 10 large drugmakers of a similar size is 11.6%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−30.8%−45.1%
FY2024−75.5%−95.0%
FY2023n/an/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a
FY2017n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY262.9%+22.4 pts−5.7%
Q1 FY26n/an/an/a
Q4 FY25−30.8%+44.7 pts−45.1%
Q3 FY25−18.7%n/a−32.7%
Q2 FY25−19.5%n/a−31.8%
Q1 FY25−10.9%n/a−22.4%
Q4 FY24−75.5%n/a−95.0%
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Arvinas' size, closest first, today.

CompanyProfit margin
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
COLLCollegium Pharmaceutical5.9%
ABUSArbutus Biopharma84.2%
NATRNatures Sunshine Products3.7%
AMPHAmphastar Pharmaceuticals10.8%
OMEROmerosn/m
PCRXPacira BioSciences2.0%
Peer median11.6%

Where Arvinas ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Arvinas

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.